secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001628280-24-049931
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem provides 2024 guidance: revenue ~$134.2M, adjusted EBITDA ~$26.5M
----------------------------------------------------------------------------

- TTM revenue through 9/30/24 $132.8M; estimated FY2024 revenue $134.2M (high single-digit growth).
- Adjusted EBITDA estimated at $26.5M for FY2024, margin ~19.7% (high teens % of revenue).
- Net leverage ratio 1.15x; debt/equity 0.90x; $20M stock repurchase program available.
- Capital allocation prioritized: organic growth, debt reduction (target leverage 1.5x-2.0x), and opportunistic buybacks.
- Patient Services gross margin improved to 66.0% TTM; Device Solutions gross margin 31.3% TTM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024049931/0001628280-24-049931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024049931/infu-20241204.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-049931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer